K-numberK243812
Device nameVolta AF-Xplorer
ApplicantVolta Medical
Product codeDQK
Device classClass II
Decision dateMay 9, 2025
DecisionSubstantially Equivalent
Regulation870.1425
AI Summary extracted from FDA summary PDF · never regenerated
Intended use

The Volta AF-Xplorer is a machine learning and deep learning-based software system that assists operators in real-time annotation of 3D anatomical and electrical heart maps to identify atrial regions with dispersed electrograms (abnormal electrical signals exhibiting spatiotemporal dispersion) in patients with atrial fibrillation or atrial tachycardia. It works with standard EP catheters and compatible data acquisition systems to display analysis results on a computer monitor outside the sterile operating room.

Technological characteristics

The subject device is technologically identical to its predicate (K232616). Both devices have the same computing platform (Intel Core i7-7700 CPU, 32GB RAM, Debian-based Linux OS), the same input (intra-cardiac multipolar signals) and output (presence or absence of electrogram dispersion), the same compatible acquisition systems (LabSystem Pro, MacLab CardioLab, EnSite X), and identical hardware design including custom analog and ethernet cables. Both support manual annotation of dispersed areas and automatic tagging via bidirectional digital communication with the 3D mapping system.

Test standards cited

Not stated in this summary.

Substantial equivalence argument

The subject device is substantially equivalent to the predicate because it is technologically identical in design, materials, computing platform, software algorithm, inputs, outputs, and intended use. The only difference is removal of qualifying language from the indications for use statement regarding clinical significance; this change is supported by the Tailored-AF clinical trial on the VX1 device (the predicate's predecessor using the same primary algorithm), which demonstrated superior effectiveness of dispersed EGM ablation versus pulmonary vein isolation alone. Since the device functionality and principles of operation remain unchanged and the updated labeling reflects new clinical evidence without altering the device's role as an electrophysiological evaluation tool, it does not raise different questions about safety and effectiveness.

Extracted by AI from the official FDA summary PDF →
Source

View the full FDA submission: accessdata.fda.gov

Researching this as a predicate?
Want a transparent AI-ranking score, AI-discovered related predicates, ongoing safety and warning-letter monitoring, full predicate chain lineage, and a drafted SE rationale — all saved to your own project? That's what an account adds.
Start free trial →

Everything you need for a 510(k) submission. Nothing you don't.

14-day free trial. No setup. Cancel anytime.

Start free trial →
Building an AI or ML-enabled device? Predicate search, PCCP tracking, and AI-specific FDA intelligence — built exclusively for AI/ML devices. Try AIFDA Intel →